HBCUs hard hit by COVID-19 crisis due to entrenched racism

first_imgAtlantaThe Philadelphia Tribune ran a March 26 article exposing how the lesser-resourced Historically Black Colleges and Universities (HBCUs) in the United States will take a harder hit than rich, predominantly white institutions (PWIs) during closures due to COVID-19.  These realities cannot be separated from the old saying: “When America catches a cold, African Americans catch the flu,” in the centuries-old struggle against white supremacy, including in the area of education.Multiple professors were interviewed by Conversation U.S. — a panel of academic experts — and gave their perspectives on varying aspects of the current health crisis facing the HBCUs.A professor at Rutgers University, Marybeth Gasman, pointed out that smaller HBCUs have few information technology specialists, and therefore, with the demand for students to work online from their homes, remote-learning situations will prove more difficult for students.Furthermore, since three-fourths of HBCU students, coming from working-class families with lower incomes, are eligible for Pell Grants, these same students may not have access to Wi-Fi or laptops. This was also a concern of Gasman. For remote learning to work successfully, students must have access to laptops and reliable Wi-Fi. Some HBCUs are lending students laptops.A professor from Howard University, Ivory A. Toldson, echoed the concerns about technology, saying many HBCU professors do not have adequate technology to be able to quickly move classes online. Again, some students may not have quality internet connections.HBCUs have smaller endowments than other institutions across the U.S. As a result, many HBCUs rely on tuition from students and less on scholarships. If students are unable to access laptops or Wi-Fi, they may drop a class, leading to the university having less money than it already had.Toldson commented that the interruptions to fundraising efforts, closed dorms and lost money from bookstores and dining halls, which all institutions are facing, will hit HBCUs particularly hard, since they had less money to begin withAdditionally, an HBCU with financial issues may lead to them losing their accreditation status. Without this status, it is “nearly impossible” to recruit students.Some HBCUs are in debt, which is one of the reasons these institutions may be building new dorms for students. With students having to leave the dorms, it is harder for certain HBCUs to pay off debt, as they are losing money as students find off-campus housing.With less government resources available to them, HBCUs lack rainy day funds, and after the COVID-19 crisis is through, some may even risk closingHBCUs also lack philanthropic funding, with PWIs receiving  $2.94 billion in donations in 2019 versus $43 million for HBCUs, according to Gregory Price, University of New Orleans economics professor.Systemically, Black families make much less money than white families on average and find it more difficult to give back to their HBCUs.HBCUs that cannot financially withstand the decline in enrollment and lack needed infrastructure, including empty leadership positions, may be at risk of declining and eventually closing.An example of an HBCU closing was St. Paul’s College in Virginia in 2013. St. Paul’s faced declines in enrollment and lost revenue.Price pointed out that multiple HBCUs have been placed on probation by regional accreditors for being financially unstable. The COVID-19 crisis may worsen the status of these HBCUs.To deal with the situation of underfunded HBCUs, some of the professors call on the federal government for financial assistance. One proposal is for a coronavirus stimulus package that includes providing $1,000 for every HBCU student, among other resources. Emergency relief for revenue loss for HBCUs was also among the proposals.FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare thislast_img read more

Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion

first_img WhatsApp Local NewsBusiness By Digital AIM Web Support – April 6, 2021 Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion Pinterest Pinterest TAGS  Twittercenter_img Previous articleZendesk To Present At Upcoming Investor ConferencesNext articleBookTrib Bites: Fun and Informative for Your Reading Delight Digital AIM Web Support Facebook Facebook GAITHERSBURG, Md.–(BUSINESS WIRE)–Feb 24, 2021– Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/ VueLife® “HP” Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire) T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients. Building upon the VueLife ® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife ® “HP” (high permeability) incorporates an innovative, patented laminate film layer that allows increased CO 2 and O 2 exchange versus other monolayer bag designs, yet maintains the scalability and process flexibility offered by a closed bag system. The increased permeability associated with the “HP” laminate layer was specifically designed for culturing cells requiring higher rates of respiration, such as T cells. “The development of this product was in direct response to the market need for a cost effective culture vessel that provides efficient cell expansion in a scalable, closed system,” said Benjamin Le Quere, General Manager for the Saint-Gobain Life Sciences Bioprocess Solutions business unit. “VueLife ® “HP” is an exciting result of the marrying of our expertise in material science with our knowledge in cell culture.” The entire family of VueLife ® cell culture bags utilize a common FEP fluid-contact layer. FEP creates an ideal environment for cell growth due to its gas permeability and liquid impermeability, while being biologically and chemically inert. ABOUT SAINT-GOBAIN LIFE SCIENCES Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery. Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain. Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 70 countries with more than 180,000 employees worldwide. The Company had €42.6 billion in sales in 2019. www.celltherapy.saint-gobain.com/products/cell-culture-processing-bags/vuelife-hp-series View source version on businesswire.com:https://www.businesswire.com/news/home/20210224005014/en/ CONTACT: Media Contact: Katy Oroszi: 330-283-3536 [email protected] KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE MARYLAND INDUSTRY KEYWORD: HEALTH FDA STEM CELLS GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Saint-Gobain Life Sciences Copyright Business Wire 2021. PUB: 02/24/2021 10:00 AM/DISC: 02/24/2021 10:01 AM http://www.businesswire.com/news/home/20210224005014/en Twitter WhatsApplast_img read more